Attenuation and protection efficacy of ORF C gene-deleted recombinant of infectious laryngotracheitis virus.

Infectious laryngotracheitis (ILT) is a highly contagious respiratory disease of chickens caused by infectious laryngotracheitis virus (ILTV). The disease is controlled by the use of live-attenuated vaccines. Previously we reported the complete nucleotide sequence of the ILTV vaccine strain (TCO) and identified a nonsense mutation in the gene encoding the ORF C protein. This suggested that the ORF C protein might be associated with viral virulence. To investigate this, an ILTV recombinant with a deletion in the gene encoding ORF C was constructed using the genome of the virulent United States Department of Agriculture (USDA) challenge strain (USDAch). Compared to the parental virus, the ΔORF C recombinant replicated in chicken kidney (CK) cells with similar kinetics and generated similar titres. This demonstrated that the ORF C deletion had no deleterious effects on replication efficacy in vitro. In chickens, the recombinant induced only minor microscopic tracheal lesions when inoculated via the intra-tracheal/ocular route, while the parental strain induced moderate to severe microscopic tracheal lesions, even though virus load in the tracheas were comparable. Groups of chickens vaccinated via eye-drop with the ∆ORFC-ILTV were protected to levels comparable to those elicited by TCO vaccination. To our knowledge, this is the first report that demonstrates the suitability of ∆ORFC as a live-attenuated vaccine to prevent the losses caused by ILTV.

Comparative full genome analysis of four infectious laryngotracheitis virus (Gallid herpesvirus-1) virulent isolates from the United States.

Gallid herpesvirus-1 (GaHV-1), commonly named infectious laryngotracheitis (ILT) virus, causes the respiratory disease in chickens known as ILT. The molecular determinants associated with differences in pathogenicity of GaHV-1 strains are not completely understood, and a comparison of genomic sequences of isolates that belong to different genotypes could help identify genes involved in virulence. Dideoxy sequencing, 454 pyrosequencing and Illumina sequencing-by-synthesis were used to determine the nucleotide sequences of four genotypes of virulent strains from GaHV-1 groups I-VI. Three hundred and twenty-five open reading frames (ORFs) were compared with those of the recently sequenced genome of the Serva vaccine strain. Only four ORFs, ORF C, U(L)37, ICP4 and U(S)2 differed in amino acid (aa) lengths among the newly sequenced genomes. Genome sequence alignments were used to identify two regions (5' terminus and the unique short/repeat short junction) that contained deletions. Seventy-eight synonymous and 118 non-synonymous amino acid substitutions were identified with the examined ORFs. Exclusive to the genome of the Serva vaccine strain, seven non-synonymous mutations were identified in the predicted translation products of the genes encoding glycoproteins gB, gE, gL and gM and three non-structural proteins U(L)28 (DNA packaging protein), U(L)5 (helicase-primase) and the immediate early protein ICP4. Furthermore, our comparative sequence analysis of published and newly sequenced GaHV-1 isolates has provided evidence placing the cleavage/packaging site (a-like sequence) within the inverted repeats instead of its placement at the 3' end of the U(L) region as annotated in the GenBank's entries NC006623 and HQ630064.

Sequence determination of variable regions within the genomes of gallid herpesvirus-2 pathotypes.

Comparative genomic studies of attenuated and virulent strains of Gallid herpesvirus 2 (GaHV-2) have identified 6 regions of sequence variability. These regions include the open reading frames (ORFs) encoding UL36 and UL49 and regions devoid of large ORFs (132-bp repeats, a-like sequences and the junctions flanking the unique short region). Our data indicate that the carboxyl terminus of UL36 contains regions of heterogeneity that are unique to CVI988-derived attenuated strains. A deletion of the TKSERT domain and a glycine(245) polymorphism in the UL49 proteins were also identified in these derivatives. Phylogenetic analyses of both UL36 and UL49 sequences indicate that CVI988-derived strains partition differently from other attenuated strains (RM-1 and R2/23), indicating that additional mutations contribute to attenuation. In very virulent and very virulent plus strains a single nucleotide polymorphism (SNP) was identified within the 132-bp tandem repeats. Within the junctions flanking the unique short region, these strains also contain deletions in sequences that are predicted to bind the transcription factor NF kappaB. In some attenuated strains, deletions were also identified in the latency-associated transcript (LAT) promoters and adjacent regions encoding microRNAs. These results indicate that virulence is likely multi-factorial with contributions from both multiple genes and cis-acting sites.

Stable ubiquitination of the ICP0R protein of herpes simplex virus type 1 during productive infection.

ICP0R is the polypeptide product of an alternatively spliced transcript of the gene encoding the transactivator protein ICP0 of herpes simplex virus type 1 (HSV-1). Although it has been shown to act as a transrepressor of gene expression in transfection assays, overexpression of the ICP0R protein in the recombinant virus HSV-KST was previously found to have no detectable effect on virus replication, so that the role it plays in HSV-1 infection remains unclear. Analysis of HSV-KST-infected cell lysates by Western blotting revealed the presence of not only the 41-kDa ICP0R polypeptide but also a 64-kDa processed form of the protein. This processing event was the result of ubiquination of the ICP0R protein, as demonstrated by the reactivity of the 64-kDa species with antibody specific for the influenza virus hemagglutinin (HA) protein epitope in experiments where the gene encoding ICP0R was coexpressed with a gene encoding HA-tagged ubiquitin. Surprisingly, the 64-kDa form of ICP0R was found to be remarkably stable and persisted in infected cells for many hours after processing, despite the fact that ubiquitination normally functions as a means of tagging proteins for rapid degradation. Analyses of mutant polypeptides containing arginine substitutions at each of the lysine residues of ICP0R, which represent potential ubiquitin conjugation sites, revealed that a single lysine residue at codon 248 was both necessary and sufficient for the appearance of the 64-kDa processed form. However, a number of ICP0R mutants that retained the ubiquitination site at lysine 248 but contained disruptions of sequences at distant sites also lacked detectable 64-kDa protein, indicating that the integrity of the overall structure of ICP0R was an additional determinant for ubiquitination.

Construction and characterization of a recombinant herpes simplex virus type 1 which overexpresses the transrepressor protein ICPOR.

ICPOR is a truncated form of the herpes simplex virus type 1 (HSV-1) transactivator protein ICPO that is synthesized at low levels during infection through an alternative splicing mechanism. In transient expression assays, ICPOR has been shown to inhibit the transactivation function of several HSV-1 regulatory proteins, suggesting that an antiviral strategy which alters normal ICPO mRNA splicing and thereby stimulates the synthesis of ICPOR protein may have potential in suppressing HSV-1 infections. To explore the feasibility of this approach, a recombinant virus was constructed which expressed high levels of ICPOR instead of ICPO. Surprisingly, overexpression of the ICPOR protein in this virus, HSV-KST, had no detectable effect on virus replication, since the growth properties of HSV-KST were indistinguishable from those of the ICPO/ICPOR null mutant dl 1403, and HSV-KST was no more efficient than dl 1403 at inhibiting the replication of an ICPO-expressing wild-type virus. The absence of a demonstrable phenotype in HSV-KST was not due to the acquisition of an inactivating mutation in the gene encoding ICPOR, since copies of the gene rescued from this virus retained full transrepression capability in transient expression assays. These results indicate that the ability of ICPOR to act as a transrepressor is significantly reduced if not completely eliminated in the context of a productive HSV-1 infection and suggest that this protein may not represent an exploitable target for the development of novel antiviral therapies.

Mutational analysis of ICP0R, a transrepressor protein created by alternative splicing of the ICP0 gene of herpes simplex virus type 1.

The immediate-early protein ICP0 (infected-cell polypeptide 0) of herpes simplex virus type 1 (HSV-1) is a promiscuous transactivator of both viral and nonviral promoters in transient expression assays. Failure to splice the second of two introns in the ICP0 gene results in the utilization of an alternate stop codon that generates a truncated form of ICP0 called ICP0R. This protein exists in low levels in HSV-1-infected cells and functions as a dominant negative repressor of ICP0-mediated transactivation in transient expression assays. To conduct a detailed structure-function analysis of ICP0R, a series of insertion and deletion mutants of this protein were generated and analyzed in transfection assays. These studies indicated that segments of ICP0R that were rich in acidic amino acid residues (amino acids 9 to 76 and 233 to 241) or glycine residues (amino acids 242 to 262) were dispensable for the dominant negative phenotype. In contrast, the RING finger domain (amino acids 116 to 156) and surprisingly the sequences carboxy terminal to it (amino acids 157 to 232) were absolutely essential for transdominant repression. Consistent with these findings, the amino acid sequences of these two regions were conserved among other alphaherpesvirus ICP0 homologs. A construct containing only amino acids 76 to 232 inhibited ICP0-mediated transactivation almost as efficiently as wild-type ICP0R and represented the minimal sequences necessary for the dominant negative phenotype. These results demonstrated that the critical functional domain shared by both ICP0R and ICP0 is much more complex than a simple RING finger motif. Western blot (immunoblot) analyses of transfected cell lysates revealed that nearly all of the mutant constructs directed the expression of stable ICP0R proteins of the predicted molecular weight. However, there was a striking inverse correlation between the ability of a mutant construct to mediate transrepression and the amount of protein that it synthesized, indicating that dominant negative inhibition is achieved through the action of very little ICP0R protein.

A feline herpesvirus-1 recombinant with a deletion in the genes for glycoproteins gI and gE is effective as a vaccine for feline rhinotracheitis.

Using a site-directed mutagenesis technique we constructed a new feline herpesvirus-1 recombinant strain containing a deletion in two genes encoding glycoproteins gI and gE. These proteins may have a role in virulence, the establishment of latency, and viral recurrence as shown in other herpesviruses of the varicella and simplex types. This recombinant was characterized and used to immunize juvenile cats against virulent virus challenge. Significant protection resulted from vaccination of cats by the subcutaneous route.

Identification of the feline herpesvirus type 1 (FHV-1) genes encoding glycoproteins G, D, I and E: expression of FHV-1 glycoprotein D in vaccinia and raccoon poxviruses.

The genome of feline herpesvirus type 1 (FHV-1), the major cause of viral upper respiratory disease in cats, contains several genes encoding homologues of herpes simplex virus type 1 (HSV-1) glycoproteins. Restriction mapping studies have indicated that the group D genome of FHV-1 contains a unique short region that is 9.0 kb long. The nucleotide sequence of a 6.2 kb portion of this region was determined. Analyses of this sequence have identified five open reading frames capable of encoding homologues to HSV-1 protein kinase and glycoproteins gG, gD, gI and gE. Since gD of FHV-1 is most likely an immunologically important polypeptide, vaccinia and raccoon poxvirus recombinants expressing this glycoprotein were generated. In an indirect fluorescent antibody test these recombinants reacted strongly with a rabbit anti-FHV-1 serum. High titres of virus-neutralizing antibodies were also generated in rabbits inoculated with the vaccinia virus recombinant. A 53K viral polypeptide (gD) was detected with this antiserum on Western blots containing polypeptides from potassium tartrate-purified virions.

Immunological characterization of the feline herpesvirus-1 glycoprotein B and analysis of its deduced amino acid sequence.

Feline herpesvirus 1 (FHV-1) is an important viral pathogen of cats. Like other alphaherpesviruses, FHV-1 contains a HSV-1 glycoprotein B (gB) homolog. In this study, monospecific antisera to HSV-1 gB reacted with three FHV-1 proteins (100, 64, and 58 kDa) present in virion lysates by immunoprecipitation and immunoblot analyses. Reduced stringency hybridization experiments using a HSV-1 gB probe localized the FHV-1 gB gene to a 9.6-kb Sa/l fragment in the unique long region of the genome. Northern blot analyses further localized the entire coding region within a 3.3-kb SacI fragment. The nucleotide sequence of this fragment was determined and two overlapping open reading frames (ORFs) encoding gB and ICP 18.5 were predicted. The amino acid sequence of the 2829 bp gB ORF was shown to have a high degree of homology with gB analogs of HSV-1, EHV-1, BHV-1, EHV-4, and especially PRV. Two unique characteristics of gB of FHV-1 were the unusually long signal sequence of 73 residues and two potential internal cleavage sites, RTRRS and RSRRS. An evolutionary tree based on gB homologs from 12 alphaherpesviruses suggests that feline herpesvirus-1 evolved along similar lines as the varicelloviruses, pseudorabies virus, bovine herpesvirus type 1, and equine herpesvirus types 1 and 4. The gB gene of FHV-1 was expressed in vaccinia virus (WR). This recombinant induced fairly high titers of virus neutralizing antibodies in rabbits. In Western blot analyses with potassium tartrate-purified virions, a 60-kDa polypeptide reacted with the rabbit antisera.

Polymerase chain reaction amplification of pseudorabies virus DNA from acutely and latently infected cells.

A characteristic of alphaherpesviruses, including pseudorabies virus (PRV), is that the acute phase of the disease is followed by lifelong latency. Latently infected animals are asymptomatic but can transmit reactivated virus. Corticosteroid administration, tissue explanation, blot- and in situ hybridizations have been used to demonstrate the presence of latent PRV infections. The use of blot hybridization as a convenient method for defining the incidence of PRV infections in swine herds has been hampered by the detection limit of this method. The objective of this study was to increase this sensitivity of blot hybridization by polymerase chain reaction (PCR) amplification of target sequences. Two sets of 20-mer primers were synthesized and used to amplify gX and gII glycoprotein gene sequences in two different strains of PRV. The specificity of the amplification was verified by Southern blot hybridization and restriction endonuclease analysis of the amplified fragments. Amplification of target sequences by PRC increased their detection limit by a factor of at least 10(5). Porcine ganglion samples, in which latency had been demonstrated by in vitro explanation, were analyzed by PCR together with positive and negative controls. Duplicate slot blot analyses of a portion of the amplified products were used to demonstrate latency in seven of eight samples. It was concluded that blot hybridization of PCR amplified DNA appears to be both a sensitive and convenient method for the detection of PRV induced latency.

Vascular malformation: report of a case with eight-year follow up.

An interesting example of a vascular malformation of the mandible has been presented. Early diagnosis made conservative treatment possible. Although the lesion was small, a considerable amount of hemorrhage was encountered during surgery. Adequate treatment was provided with ligation of external carotid arteries bilaterally in conjunction with curettage and packing. After an eight-year follow up, there has been no clinical or radiographic evidence of recurrence.

Erythema nodosum in Sweet's syndrome.

A 36-year-old man had Sweet's syndrome associated with plaques on the legs that were typical of erythema nodosum both clinically and histologically. To our knowledge, true erythema nodosum has not previously been recognized as part of Sweet's syndrome.

Mycophenolic acid in psoriasis.

Mycophenolic acid (MPA) is a fermentation product of a penicillium mould which has shown antitumour acitivity in certain animal models. It blocks nucleic acid synthesis by interfering with the interconversions of inosine monophosphate (IMP), xanthine monophosphate (XMP) and guanine monophosphate (GMP) thereby inhibiting growth and/or replication of tumour cells. In vivo activity depends on the presence of a beta-glucuronidase which is abundant in the cell wall of epithelial tissues. Encouraged by results obtained in earlier clinical trials, we have studied 28 patients with psoriasis, 21 in double-blind fashion. A comparison of disease severity in patients before and after receiving MPA versus patients receiving placebo clearly showed the superiority of drug over placebo. The mean severity score of patients receiving MPA as an initial course of therapy improved by 56% versus 9% in patients receiving placebo. Patients receiving MPA after an initial course of placebo therapy showed improvement in their mean severity score averaging 86%. Those patients receiving placebo after an initial course of MPA showed worsening of their mean severity score averaging 70%. Overall, about 75% of MPA treated patients have shown good to excellent responses, and toxicity appears low. Evidence suggests that MPA may be very useful in treating severe psoriasis.